Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Current Liabilities (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Total Current Liabilities for 9 consecutive years, with $45.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 4.13% to $45.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.4 million through Dec 2025, down 4.13% year-over-year, with the annual reading at $45.4 million for FY2025, 4.13% down from the prior year.
  • Total Current Liabilities hit $45.4 million in Q4 2025 for Protagonist Therapeutics, up from $44.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $47.4 million in Q4 2024 to a low of $21.3 million in Q4 2023.
  • Historically, Total Current Liabilities has averaged $37.3 million across 5 years, with a median of $39.5 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: plummeted 46.55% in 2023 and later skyrocketed 122.8% in 2024.
  • Year by year, Total Current Liabilities stood at $44.0 million in 2021, then dropped by 29.16% to $31.2 million in 2022, then tumbled by 31.77% to $21.3 million in 2023, then surged by 122.8% to $47.4 million in 2024, then fell by 4.13% to $45.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for PTGX at $45.4 million in Q4 2025, $44.9 million in Q3 2025, and $35.5 million in Q2 2025.